Skip to main content

Delcath Systems Value Stock - Dividend - Research Selection

Delcath systems

ISIN: US24661P5008 , WKN: A2AP0C

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Delcath Systems, Inc. (Delcath) is a pharmaceutical and medical device company specializing in oncology that focuses on developing medicines and initially causes cancer in the liver. Delcath focuses on the development and clinical study of the Delcath chemosuppressive system. The Delcath chemosaturation system allows the administration of concentrated regional chemotherapy by isolating the circulatory system of the target organ. Once the organ is isolated, the Delcath chemosuppression system delivers doses of chemotherapeutic agents directly to the liver. The Delcath chemosuppression system includes a series of three catheter insertions, each of which is placed percutaneously by interventional radiology techniques. The procedure is minimally invasive and repeatable, allowing for multiple treatment cycles with chemotherapeutic drugs. On April 13, 2011, it received the Conformite Europeenne (CE) mark for the Delcath Hepatic CHEMOSAT Delivery System (CHEMOSAT System).

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Delcath Systems to Participate at the BTIG Annual MedTech, Digital Health, Life Science and Diagnostic Tools Conference

2025-01-29
QUEENSBURY - Delcath Systems, Inc. , an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the...

Delcath Systems to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

2025-01-28
Delcath Systems, Inc. , an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the BTIG Annual...

Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results

2025-01-13
Fourth Quarter Revenue Approximately $15.1 Million and Full Year Total Revenue Approximately $37.2 Million...

Total Return Breakouts: Forensic Anomalies, NVIDIA, And A Bullish Energy Sector Signal

2025-01-06

Delcath Announces Inducement Grant under Nasdaq Listing Rule 5635(4)

2025-01-06
QUEENSBURY - Delcath Systems, Inc. , an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted an equity award,...

Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

2025-01-03
QUEENSBURY, N.Y., January 03, 2025--Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted an equity award, previously approved by the Company’s Compensation Committee, as a material inducement to the employment of an individual whose employment commenced on November 4, 2024.

Delcath Systems Announces Additional $16.3 Million in Funding From Series E and E1 Warrant Exercises

2024-12-30
QUEENSBURY, N.Y., December 30, 2024--Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the exercise of 1.7 million Series E and E1 warrants which resulted in $16.3 million of funding. Approximately 6.6% of the warrants exercised were subject to cashless exercise provisions. The warrants, issued in July and August 2019 as a component of a private placement,

3 US Growth Companies To Watch With Up To 32% Insider Ownership

2024-12-30
As the United States stock market navigates a volatile period marked by fluctuations in major indices and a notable slump in big-tech stocks, investors are increasingly focused on identifying resilient growth opportunities. In this environment, companies with substantial insider ownership can offer unique insights into potential value creation, as insiders' vested interests often align with long-term shareholder success.

Delcath : Announces Additional $16.3 Million in Funding From Series E and E1 Warrant Exercises Form 8 K

2024-12-30
Delcath Systems Announces Additional $16.3 Million in Funding From Series E and E1 Warrant Exercises QUEENSBURY, NY - December 30, 2024, Delcath Systems,...

Analysts Expect Breakeven For Delcath Systems, Inc. (NASDAQ:DCTH) Before Long

2024-12-29
We feel now is a pretty good time to analyse Delcath Systems, Inc.'s ( NASDAQ:DCTH ) business as it appears the company...